Systematic review update and meta-analysis of randomized and non-randomized controlled trials of ovarian stimulation versus artificial cycle for endometrial preparation prior to frozen embryo transfer in women with polycystic ovary syndrome.


Journal

Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627

Informations de publication

Date de publication:
02 Apr 2022
Historique:
received: 23 12 2021
accepted: 21 03 2022
entrez: 3 4 2022
pubmed: 4 4 2022
medline: 6 4 2022
Statut: epublish

Résumé

This systematic review and meta-analysis aimed to compare the short-term reproductive and long-term obstetric outcomes after endometrial preparations by ovarian stimulation protocols and hormone replacement therapy (HRT) in women with polycystic ovary syndrome (PCOS) prior to frozen embryo transfer (FET). PubMed, EMBASE, Web of Science and the Cochrane Library were searched to identify relevant studies. Primary outcome was live birth rate, secondary outcomes included the rates of clinical pregnancy, miscarriage, implantation and hCG-postive, cycle cancellation, ectopic pregnancy, preterm birth, preeclampsia, gestational hypertension, gestational diabetes mellitus and abnormal placentation. Nine studies, including 8327 patients with PCOS, were identified. Live birth rate was significantly higher (RR = 1.11, 95% CI = 1.03-1.19) and miscarriage rate (RR = 0.60, 95% CI = 0.46-0.78) was significantly lower in stimulated protocol compared to the rates in HRT. While the rates of ongoing pregnancy, clinical pregnancy, implantation, hCG-positive, cycle cancellation and ectopic pregnancy showed no significant difference between the two protocols. Compared HRT with different stimulation protocols, significantly higher clinical pregnancy rate (RR = 1.54, 95% CI = 1.20-1.98) were found in letrozole group, but not in the other subgroups. For the obstetric outcomes, the preterm birth and preeclampsia rates were significantly lower in the stimulated group compared to that in the HRT group (RR = 0.85, 95% CI = 0.74-0.98; RR = 0.57, 95% CI = 0.40-0.82, respectively), while gestational hypertension, gestational diabetes mellitus and abnormal placentation rates showed no significant difference. The present data suggest that ovarian stimulation protocol as an endometrial preparation regimen prior to FET might be superior to HRT protocol with a significantly higher rate of live birth, lower risk of miscarriage, preterm birth and preeclampsia. Our study showed stimulated protocol is better than HRT regimen as an endometrial preparation for women with PCOS. However, quality of the evidence is low, more well-designed RCT studies are still needed to confirm the results before clinical recommendation, particularly direct comparisons between letrozole and other stimulated regimens.

Identifiants

pubmed: 35366912
doi: 10.1186/s12958-022-00931-4
pii: 10.1186/s12958-022-00931-4
pmc: PMC8976372
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

62

Informations de copyright

© 2022. The Author(s).

Références

Drug Des Devel Ther. 2015 Nov 11;9:6001-8
pubmed: 26648691
Front Endocrinol (Lausanne). 2020 Sep 30;11:546532
pubmed: 33101194
Hum Reprod. 2020 Jul 1;35(7):1612-1622
pubmed: 32681726
J Clin Med. 2021 Feb 11;10(4):
pubmed: 33670133
J Clin Endocrinol Metab. 2015 May;100(5):1742-7
pubmed: 25710566
Drug Des Devel Ther. 2021 Jun 28;15:2805-2813
pubmed: 34234412
Am J Obstet Gynecol. 2021 Jul;225(1):59.e1-59.e9
pubmed: 33529574
Hypertension. 2019 Mar;73(3):640-649
pubmed: 30636552
Fertil Steril. 2012 Dec;98(6):1356-8
pubmed: 23062732
Hum Reprod. 2020 Jul 1;35(7):1623-1629
pubmed: 32478389
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Hum Fertil (Camb). 2014 Dec;17(4):257-68
pubmed: 25380089
J Clin Pharm Ther. 2019 Aug;44(4):618-622
pubmed: 30868612
Hum Reprod. 2021 Feb 18;36(3):683-692
pubmed: 33340402
Nat Rev Endocrinol. 2018 May;14(5):270-284
pubmed: 29569621
J Assist Reprod Genet. 2019 May;36(5):925-933
pubmed: 30924053
Front Endocrinol (Lausanne). 2021 Jul 09;12:688237
pubmed: 34305815
Reprod Biol Endocrinol. 2020 Nov 20;18(1):115
pubmed: 33218350
Acta Obstet Gynecol Scand. 2021 Jun;100(6):1116-1123
pubmed: 33616957
Pregnancy Hypertens. 2020 Oct;22:47-53
pubmed: 32738589
J Assist Reprod Genet. 2021 Nov;38(11):2925-2931
pubmed: 34537928
Hum Reprod. 2018 Oct 1;33(10):1907-1914
pubmed: 30239784
Reprod Biol Endocrinol. 2020 May 4;18(1):36
pubmed: 32366332
Fertil Steril. 2022 Jan;117(1):96-103
pubmed: 34548167
Am J Perinatol. 2016 Feb;33(3):258-66
pubmed: 26731184
Hum Reprod Update. 2016 Sep;22(5):647-64
pubmed: 27385360
J Hum Reprod Sci. 2011 May;4(2):70-5
pubmed: 22065820
Fertil Steril. 2003 Nov;80(5):1228-33
pubmed: 14607580
J Assist Reprod Genet. 2016 Nov;33(11):1419-1430
pubmed: 27480540
Endocr Rev. 2009 Feb;30(1):1-50
pubmed: 19056992
Hum Reprod. 2017 Jun 1;32(6):1244-1248
pubmed: 28398491
Clin Obstet Gynecol. 2011 Dec;54(4):685-95
pubmed: 22031258
Semin Reprod Med. 2017 Jul;35(4):359-363
pubmed: 29036743
Hum Reprod. 2021 Aug 18;36(9):2421-2428
pubmed: 34333641
Hum Reprod Update. 2021 Apr 21;27(3):584-618
pubmed: 33302299
Front Endocrinol (Lausanne). 2021 Jan 18;11:532692
pubmed: 33537000
Hum Reprod. 2016 Jul;31(7):1483-92
pubmed: 27179265
Syst Biol Reprod Med. 2014 Apr;60(2):105-11
pubmed: 24304327
Hum Reprod Update. 2021 Jun 22;27(4):651-672
pubmed: 33748839
Gynecol Endocrinol. 2019 Oct;35(10):862-865
pubmed: 31081404
Drug Des Devel Ther. 2019 Nov 14;13:3867-3877
pubmed: 31814708
Pregnancy Hypertens. 2012 Apr 1;2(2):72-83
pubmed: 22745921
Hum Reprod. 2012 Mar;27(3):881-8
pubmed: 22246449
Arch Gynecol Obstet. 2012 Dec;286(6):1581-7
pubmed: 22829102
N Engl J Med. 2016 Aug 11;375(6):523-33
pubmed: 27509101
Fertil Steril. 2019 Aug;112(2):371-377
pubmed: 31126712
Gynecol Endocrinol. 2021 Apr;37(4):294-299
pubmed: 33426930
Reprod Med Biol. 2019 May 24;18(3):234-240
pubmed: 31312101

Auteurs

Yingying Zhang (Y)

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.

Ling Wu (L)

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.

Tin Chiu Li (TC)

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.

Chi Chiu Wang (CC)

Department of Obstetrics and Gynaecology, Li Ka Shing Institute of Health Sciences, School of Biomedical Sciences, Chinese University of Hong Kong -Sichuan University Joint Laboratory in Reproductive Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

Tao Zhang (T)

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China. taozhang@cuhk.edu.hk.

Jacqueline Pui Wah Chung (JPW)

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China. jacquelinechung@cuhk.edu.hk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH